Literature DB >> 22952065

Evaluation of alkylmaltosides as intestinal permeation enhancers: comparison between rat intestinal mucosal sheets and Caco-2 monolayers.

Signe Beck Petersen1, Gavin Nolan, Sam Maher, Ulrik Lytt Rahbek, Mette Guldbrandt, David J Brayden.   

Abstract

Alkylmaltosides are a class of non-ionic surfactant currently in clinical trials to improve nasal permeation of peptide drugs, however few studies have detailed their potential effects on intestinal permeation enhancement. Tetradecyl maltoside (TDM, C(14)), was examined in Caco-2 monolayers and in isolated rat jejunal and colonic mucosae mounted in Ussing chambers. Dodecyl maltoside (DDM, C(12)) was examined in mucosae. Parameters measured included critical micelle concentration (CMC), transepithelial electrical resistance (TEER), and apparent permeability coefficients (P(app)) of paracellular and transcellular flux markers. TDM and DDM decreased TEER and increased the P(app) of [(14)C]-mannitol and FD-4 across Caco-2 monolayers and colonic mucosae in the concentration range of 0.01-0.1% w/v, concentrations much higher than the CMC. Remarkably, neither agent had any effect on the TEER or fluxes of jejunal mucosae. Histopathology, cell death assays (MTT and LDH) and sub-lethal high content cytotoxicity analyses (HCA) were carried out with TDM. Exposure of colonic mucosae to high concentrations of TDM had no major effects on gross histology and ion transport function was retained. In Caco-2, HCA data at sub-lethal concentrations of TDM was consistent with the action of a mild non-ionic surfactant. In conclusion, alkylmaltosides are effective non-toxic permeation enhancers in isolated colonic tissue and their inclusion in oral peptide formulations directed to that intestinal region warrants further study.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22952065     DOI: 10.1016/j.ejps.2012.08.010

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  8 in total

Review 1.  Safety concerns over the use of intestinal permeation enhancers: A mini-review.

Authors:  Fiona McCartney; John P Gleeson; David J Brayden
Journal:  Tissue Barriers       Date:  2016-04-12

2.  Investigations of Piperazine Derivatives as Intestinal Permeation Enhancers in Isolated Rat Intestinal Tissue Mucosae.

Authors:  V Stuettgen; D J Brayden
Journal:  AAPS J       Date:  2020-01-27       Impact factor: 4.009

3.  Development of a Non-Aqueous Dispersion to Improve Intestinal Epithelial Flux of Poorly Permeable Macromolecules.

Authors:  Sam Maher; Mekki Medani; Nestor N Carballeira; Desmond C Winter; Alan W Baird; David J Brayden
Journal:  AAPS J       Date:  2016-10-13       Impact factor: 4.009

4.  An Assessment of the Permeation Enhancer, 1-phenyl-piperazine (PPZ), on Paracellular Flux Across Rat Intestinal Mucosae in Ussing Chambers.

Authors:  V A Bzik; D J Brayden
Journal:  Pharm Res       Date:  2016-07-07       Impact factor: 4.200

5.  Efficacious intestinal permeation enhancement induced by the sodium salt of 10-undecylenic acid, a medium chain fatty acid derivative.

Authors:  David J Brayden; Edwin Walsh
Journal:  AAPS J       Date:  2014-06-25       Impact factor: 4.009

6.  Evaluation of Sucrose Laurate as an Intestinal Permeation Enhancer for Macromolecules: Ex Vivo and In Vivo Studies.

Authors:  Fiona McCartney; Mónica Rosa; David J Brayden
Journal:  Pharmaceutics       Date:  2019-10-31       Impact factor: 6.321

7.  Transepithelial transport of PAMAM dendrimers across isolated rat jejunal mucosae in ussing chambers.

Authors:  Dallin Hubbard; Hamidreza Ghandehari; David J Brayden
Journal:  Biomacromolecules       Date:  2014-07-03       Impact factor: 6.988

8.  A multi-chamber microfluidic intestinal barrier model using Caco-2 cells for drug transport studies.

Authors:  Hsih-Yin Tan; Sofie Trier; Ulrik L Rahbek; Martin Dufva; Jörg P Kutter; Thomas L Andresen
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.